Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 120 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Interferon Gamma Clear all

Conditions: Healthy, Mycobacterium Infections, Atypical
Interventions: interferon gamma; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: IFN-Gamma Therapy, CGD Gene Mutation, CGD Response to IFNg, CGD - Chronic Granulomatous Disease, Immunodeficiency Disease
Interventions: IFN-gamma; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Lung Disease
Interventions: Interferon gamma-1b; Drug
Lead sponsor: InterMune; Industry
Eligibility: Not listed
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Stem Cell Transplantation
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Myxoid Liposarcoma, Round Cell Liposarcoma, Synovial Sarcoma
Interventions: Laboratory Biomarker Analysis, Recombinant Interferon Gamma; Other · Biological
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hepatitis B
Interventions: IFN-γ 1b (Actimmune), Adefovir dipivoxil, IFN-γ 1b and Adefovir dipivoxil combination; Drug
Lead sponsor: Huntington Medical Research Institutes; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Crohn's Disease, Colitis, Intestinal Disease, Gastrointestinal Disease, Digestive System Disease
Interventions: anti-Interferon-gamma monoclonal antibody; Drug
Lead sponsor: Facet Biotech; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 15
States / cities: Anaheim, California • Orange, California • Gainesville, Florida + 12 more

Conditions: Inherited Ophthalmic Diseases, Inherited Retinal Degeneration
Interventions: Interferon gamma-1b; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 12 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Mycobacterium Infections, Tuberculosis, Multidrug-Resistant, Latent Tuberculosis, Tuberculosis, Extensively Drug-Resistant Tuberculosis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 100 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions: fluorouracil, sodium phenylbutyrate, indomethacin, recombinant interferon gamma; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: New York, New York

Conditions: Infection, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: recombinant interferon gamma, voriconazole; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 3
States / cities: Little Rock, Arkansas • Gainesville, Florida • Bethesda, Maryland

Conditions: Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic, Arthritis, Juvenile, Adult Onset Still Disease
Interventions: Emapalumab; Drug
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 0 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections
Interventions: Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, Epstein-Barr Virus Specific T-Lymphocytes; Biological
Lead sponsor: Jessie L. Alexander; Other
Eligibility: 1 Month to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Palo Alto, California

Conditions: Chronic Granulomatous Disease
Interventions: Interferon Gamma-1B; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 5 Years to 60 Years
Enrollment: 9 participants
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus
Interventions: Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, EBV Specific T-Lymphocytes; Biological
Lead sponsor: Jessie L. Alexander, MD; Other
Eligibility: 1 Month to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Mycobacterium Avium-Intracellulare Infection
Interventions: Interferon Gamma for Aerosol; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Hodgkin's Lymphoma
Interventions: Interferon Gamma-1b, Rituximab; Drug
Lead sponsor: InterMune; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: Carboplatin, GM-CSF (Sargramostim), Interferon Gamma; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: filgrastim, recombinant interferon gamma, tumor cell lysate vaccine therapy; Biological
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2006
U.S. locations: 4
States / cities: Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 1 more

Conditions: Soft Tissue Sarcoma Adult
Interventions: Multiple drug microinjection, CIVO device; Drug · Device
Lead sponsor: Presage Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 3
States / cities: Lake Success, New York • Portland, Oregon • Seattle, Washington

Conditions: Active Tuberculosis, Latent Tuberculosis Infection, Non-Tuberculous Mycobacterial (NTM) Pneumonia
Interventions: Blood draw and IGRA test; Diagnostic Test
Lead sponsor: BioMérieux; Industry
Eligibility: 2 Years and older
Enrollment: 2,401 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 7
States / cities: Palo Alto, California • San Diego, California • Denver, Colorado + 4 more

Conditions: Leukocyte Adhesion Deficiency Syndrome
Interventions: Interferon gamma; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Positive
Interventions: Not listed
Lead sponsor: QIAGEN Gaithersburg, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Interventions: Pembrolizumab, Carboplatin, Paclitaxel; Drug
Lead sponsor: Dan Zandberg; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Treatment of Non-Tuberculous Mycobacterial Infections With Interferon Gamma

Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease

An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF

Investigating Cytokine Genes of Stem Cell Donors

Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma

A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B

A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease

Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)

Training Protocol on the Natural History of Tuberculosis

Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer

Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections

A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)

Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity

Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease

Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV

A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections

Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer

Tumor Cell Vaccine in Treating Patients With Advanced Cancer

Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

Performance Evaluation of the VIDAS TB-IGRA Assay.

Interferon Gamma to Treat Leukocyte Adhesion Deficiency Type I

Evaluation of a Blood Test to Measure Immune Function in HIV Positive People Compared With HIV Negative People

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC